GRPR and prostate carcinoma: BB2 receptor blockade was selected for our experiments based on the fact that prostate carcinomas and PC-3 cells in specific are known to abundantly express GRP-R [23,27,30] and that the mitogenic/proliferative effects of BBS in prostate and other types of cancer are predominantly mediated via BB2 receptor [28,46].